EWTX vs NVS
Edgewise Therapeutics, Inc. vs Novartis AG — AI-powered side-by-side comparison
EWTX
Edgewise Therapeutics, Inc.
61
Buy
VS
| Metric | EWTX | NVS |
|---|
| AI Score |
61
|
75
|
| Price |
$44.30
|
$154.64
|
| P/E Ratio |
-23.95×
|
23.55×
|
| ROE |
-32.1%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
74.3%
|
| Debt / Equity |
0.01×
|
1.18×
|
| Dividend Yield |
0.0%
|
2.9%
|
| RSI (14) |
61.0
|
57.7
|
| Beta |
0.275
|
0.462
|
| Expected Upside |
—
|
+2.4%
|
AI Committee View
Current Innellis committee reasoning for EWTX versus NVS.
NVS leads by 14 points.
NVS scores 75/100 (Buy) versus EWTX at 61/100 (Buy).
EWTX Committee View
60% agreement
5 analysts
Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- Price-to-book of 5.0x prices in significant intangible value — Value
- ROE of only -39.0% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 23.8% signals elevated volatility — Risk
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical